Alamar Biosciences initiated with a Neutral at BofA

BofA initiated coverage of Alamar Biosciences (ALMR) with a Neutral rating and $27 price target The emerging growth life science tools company with a cutting edge platform for the study of proteomics is targeting a “large, early-stage market,” with major opportunities in research, translational, and clinical applications, the analyst tells investors. However, the firm believes much of the upside is already priced in at the current valuation.